Crescent Biopharma stock
CBIONASDAQCrescent Biopharma, Inc., HealthcareISIN KYG2545C1042
33Score 33 out of 100, Weak
Price and trend
47 / 100
Price history
+10% in one yearThe chart shows daily closes over 13 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 9.8% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 62).
The price is 47% below its 52-week high. Largest decline in 13 years: 100% (February 2018 to February 2026).
Chart figures for advanced users
- SMA 50$14.93
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$15.93
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)62
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$8.94
- The lowest closing price of the last twelve months.
- Resistance$26.98
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Crescent Biopharma, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $533.76M, is number 237 of 289 companies in its industry on MEQIRI.
- MEQIRI Score 33 out of 100 (Weak): rank 639 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $289.36M, financial debt $2.46M.Stability 54
Weaknesses
- Loss-makingLoss of $162.98M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$144.45M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 81% a year over the last 12 months.Stability 54
The score is held back by profitability and capital allocation.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
From 2025 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −1408%, net −1420%. Last 12 months: net −100%. From 2025 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 12 Nov 2026EPS reported −$0.90 (expected −$0.70)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$3.080.0%
- Revenue
- $1.87M0.0%
- Earnings per share
- −$2.910.0%
- Revenue
- $4.79M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $12.38M in total. 7 insiders sold, $1.51M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Brumm Joshua TSale
18 Sept 2026, Chief Executive Officer
- Shares
- 7,837
- Price
- $16.71
- Value
- $130,956
- McNeill JonathanSale
18 Sept 2026, President and COO
- Shares
- 3,839
- Price
- $16.71
- Value
- $64,150
- Lynch RyanSale
16 Sept 2026, See Remarks
- Shares
- 240
- Price
- $17.90
- Value
- $4,296
Show 14 more
- Pinkas JanSale
16 Sept 2026, Chief Scientific Officer
- Shares
- 658
- Price
- $17.90
- Value
- $11,778
- Im Ellie EunkyungSale
16 Sept 2026, Chief Medical Officer
- Shares
- 623
- Price
- $17.90
- Value
- $11,152
- Scalzo Richard WilliamSale
16 Sept 2026, Chief Financial Officer
- Shares
- 568
- Price
- $17.90
- Value
- $10,167
- Bispham Barbara HarlinSale
16 Sept 2026, See Remarks
- Shares
- 620
- Price
- $17.90
- Value
- $11,098
- Brumm Joshua TSale
16 Sept 2026, Chief Executive Officer
- Shares
- 1,610
- Price
- $17.90
- Value
- $28,819
- McNeill JonathanSale
16 Sept 2026, President and COO
- Shares
- 731
- Price
- $17.90
- Value
- $13,085
- Fairmount Funds Management LLCPurchase
16 Jul 2026, Board
- Shares
- 853,450
- Price
- $14.50
- Value
- $12.38M
- Lynch RyanSale
22 Jun 2026, See Remarks
- Shares
- 465
- Price
- $17.99
- Value
- $8,365
- Pinkas JanSale
22 Jun 2026, Chief Scientific Officer
- Shares
- 1,288
- Price
- $17.99
- Value
- $23,171
- Scalzo Richard WilliamSale
22 Jun 2026, Chief Financial Officer
- Shares
- 1,112
- Price
- $17.99
- Value
- $20,005
- Bispham Barbara HarlinSale
22 Jun 2026, See Remarks
- Shares
- 1,218
- Price
- $17.99
- Value
- $21,912
- Im Ellie EunkyungSale
22 Jun 2026, Chief Medical Officer
- Shares
- 1,219
- Price
- $17.99
- Value
- $21,930
- McNeill JonathanSale
22 Jun 2026, President and COO
- Shares
- 20,549
- Price
- $17.99
- Value
- $369,677
- Brumm Joshua TSale
22 Jun 2026, Chief Executive Officer
- Shares
- 42,305
- Price
- $17.99
- Value
- $761,067
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Crescent Biopharma
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 33
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Entera BioENTX $560.72M44
- Adlai NortyeANL $558.4M36
- ValnevaVLA.PA $554.46M29
- Helus PharmaHELP $549.18M39
- REGENXBIORGNX $530.96M34
- Eupraxia PharmaceuticalsEPRX $525.16M44
- Egetis TherapeuticsEGTX.ST $518.45M42
- Phathom PharmaceuticalsPHAT $506.45M29
ETFs that hold Crescent Biopharma
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.28B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.